Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

Naveed Sattar¹ · David Fitchett² · Stefan Hantel³ · Jyothis T. George³ · Bernard Zinman⁴

Abstract

Aims/hypothesis In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes.

Methods Changes from baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed in the EMPA-REG OUTCOME® trial (n = 7020), pooled data from four 24-week placebo-controlled trials (n = 2477) and a trial of empagliflozin vs glimepiride over 104 weeks (n = 1545). Analyses were performed using data from all participants and by tertiles of baseline aminotransferases.

Results In the EMPA-REG OUTCOME® trial, mean ± SE changes from baseline ALT at week 28 were −2.96 ± 0.18 and −0.73 ± 0.25 U/l with empagliflozin and placebo, respectively (adjusted mean difference: −2.22 [95% CI −2.83, −1.62]; p < 0.0001). Reductions in ALT were greatest in the highest ALT tertile (placebo-adjusted mean difference at week 28: −4.36 U/l [95% CI −5.51, −3.21]; p < 0.0001). The adjusted mean difference in change in ALT was −3.15 U/l (95% CI −4.11, −2.18) with empagliflozin vs placebo at week 24 in pooled 24-week data, and −4.88 U/l (95% CI −6.68, −3.09) with empagliflozin vs glimepiride at week 28. ALT reductions were largely independent of changes in weight or HbA1c. AST changes showed similar patterns to ALT, but the reductions were considerably lower.

Conclusions/interpretation These highly consistent results suggest that empagliflozin reduces aminotransferases in individuals with type 2 diabetes, in a pattern (reductions in ALT>AST) that is potentially consistent with a reduction in liver fat, especially when ALT levels are high.

Keywords Alanine aminotransferase · Aspartate aminotransferase · Non-alcoholic fatty liver disease · Sodium glucose cotransporter 2 inhibition · Type 2 diabetes mellitus

Introduction

Non-alcoholic fatty liver disease (NAFLD) is estimated to affect more than half of those with type 2 diabetes [1–3]. The first recognisable stage of NAFLD is hepatic steatosis,
when the fat content exceeds 5% of the liver volume [4]. Mechanistic insights suggest that ectopic liver fat is probably part of the pathogenic process in diabetes, contributing to hepatic insulin resistance, excess gluconeogenesis and higher fasting glucose levels [5]. Furthermore, hepatic steatosis due to NAFLD leads to, and is often clinically suspected by, increased levels of aminotransferases, with levels of alanine aminotransferase (ALT) exceeding those of aspartate aminotransferase (AST) [4]. Elevated ALT levels (typically >40–50 U/l) are common in individuals with type 2 diabetes [6–8] and for a given serum ALT, those with type 2 diabetes have more liver fat compared with BMI-, age- and sex-matched individuals without diabetes [9]. In a minority of individuals, hepatic steatosis progresses to non-alcoholic steatohepatitis (NASH), at which point liver inflammation and fibrosis necessitate monitoring and interventions to prevent progression to cirrhosis and other life-threatening sequelae [4]. In individuals with type 2 diabetes and elevated liver enzymes or NAFLD, improved glucose control may be important to delay the progression of liver disease [10, 11]. The glucose-lowering agents pioglitazone [12] and liraglutide [13] have been shown to reduce liver fat in individuals with NASH with and without type 2 diabetes, but the effects of newer agents on liver fat are less well studied.

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce hyperglycaemia in individuals with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering HbA1c [14]. Empagliflozin, a highly selective SGLT2 inhibitor, was the first glucose-lowering agent to demonstrate a reduction in cardiovascular outcomes in individuals with type 2 diabetes and established cardiovascular disease, driven by a 38% reduction in cardiovascular death vs placebo [15]. Empagliflozin is associated with weight loss [15–22], probably due to osmotic diuresis and loss of calories in the urine [14, 23]. Nearly 90% of the weight loss with empagliflozin is due to a reduction in fat mass, with reductions in both abdominal visceral and subcutaneous adipose tissue [22]. This, in addition to improvements in other adiposity markers with empagliflozin [24], led us to hypothesise that empagliflozin may improve liver fat.

In the current analyses, we investigated the effects of empagliflozin on ALT and AST using several datasets collected in individuals with type 2 diabetes: the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease [15], pooled data from four Phase III trials [16–19] and a head-to-head trial of empagliflozin vs glimepiride [22]. Given that empagliflozin therapy is associated with weight loss, we hypothesised that empagliflozin would lower ALT and AST, with greater reductions in ALT than AST, and that absolute reductions would be most evident in participants with higher ALT levels at baseline. We also investigated the contribution of weight loss and reduction in HbA1c to improvements in ALT.
Methods

Study participants The effect of empagliflozin on liver enzymes was analysed from three data sources. First, in the EMPA-REG OUTCOME® trial (NCT01131676), participants with type 2 diabetes (HbA1c 53–75 mmol/mol [7–9%] for drug-naive participants and 53–86 mmol/mol [7–10%] for those on stable glucose-lowering therapy), established cardiovascular disease, BMI ≤45 kg/m², and eGFR (according to Modification of Diet in Renal Disease [MDRD]) ≥30 ml/min/1.73 m² were randomised 1:1:1 to receive empagliflozin 10 mg, empagliflozin 25 mg or placebo once daily. Background glucose-lowering therapy was to remain unchanged for 12 weeks. After week 12, investigators were encouraged to adjust glucose-lowering therapy to achieve glycemic control according to local guidelines. They were also encouraged to treat cardiovascular risk factors to achieve the best standard of care according to local guidelines throughout the trial. The trial was planned to continue until at least 691 participants had experienced an adjudicated event included in the primary outcome (three-point major adverse cardiovascular events: composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) [15].

Second, liver enzyme data from four Phase III trials in participants with type 2 diabetes were pooled. In these trials, participants with BMI ≤45 kg/m², eGFR (MDRD) ≥30 ml/min/1.73 m² (or ≥50 ml/min/1.73 m² in the monotherapy trial) and HbA1c ≥53 to ≤86 mmol/mol (≥7 to ≤10%) were randomised 1:1:1 to receive empagliflozin 10 mg, empagliflozin 25 mg or placebo once daily for 24 weeks as monotherapy (NCT01177813) [16], add-on to metformin (NCT01159600) [17], add-on to metformin plus sulfonylurea (NCT01159600) [18] or add-on to pioglitazone with or without metformin (NCT01210001) [19]. Rescue medication could be initiated if, after an overnight fast, a participant had a confirmed plasma glucose concentration of >13.3 mmol/l during weeks 1–12 or >11.1 mmol/l during weeks 12–24.

Finally, liver enzyme data were analysed in the initial 104-week period of the EMPA-REG H2H-SU trial, in which participants with type 2 diabetes, BMI ≤45 kg/m², HbA1c 53–86 mmol/mol (7–10%) and eGFR (MDRD) ≥60 ml/min/1.73 m² were randomised 1:1 to receive once-daily empagliflozin 25 mg or glimepiride 1–4 mg as add-on to metformin (NCT01167881) [22]. Glimepiride was initiated at a dose of 1 mg/day, with a recommendation for uptitration if fasting plasma glucose (assessed with home monitoring) was >6.1 mmol/l, to 2 mg/day at week 4, 3 mg/day at week 8 and 4 mg/day at week 12. Rescue medication could be initiated if, after an overnight fast, a participant had a confirmed blood glucose concentration of >13.3 mmol/l during weeks 1–12, >11.1 mmol/l during weeks 12–28 or >10.0 mmol/l (or HbA1c >64 mmol/mol (>8%)) after week 28.

For all the trials that contributed data to these analyses, the clinical trial protocol was approved by the relevant institutional review boards and local independent ethics committees, and all of the trials were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice. Participants provided signed and dated informed consent before entering each trial.

ALT and AST measurements In the EMPA-REG OUTCOME® trial, samples for analysis of liver aminotransferases were taken during study visits at baseline and weeks 4, 12, 28 and 52, and then every 14 weeks until the end of the trial. In the 24-week placebo-controlled trials, samples for analysis of liver aminotransferases were taken during study visits at baseline and at weeks 12 and 24. In the initial 104 weeks of the EMPA-REG H2H-SU trial, samples for analysis of liver aminotransferases were taken during study visits at baseline and at weeks 12, 28, 52, 78 and 104. In all studies, analyses of liver aminotransferases were performed by a central laboratory.

Analysis Changes from baseline in ALT and AST were assessed using mixed-model repeated measures (MMRM) analyses, including baseline ALT or AST and baseline HbA1c as linear covariates and region, baseline BMI, baseline eGFR, study, treatment, visit, baseline HbA1c by visit interaction, baseline ALT or AST by visit interaction and visit by treatment interaction as fixed effects. The analysis of EMPA-REG OUTCOME® data included an additional factor for the last week a participant could have had an ALT or AST measurement. MMRM analyses were based on observed cases, including values after initiation of rescue medication. In analyses of EMPA-REG OUTCOME® and pooled data from the 24-week trials, analyses were performed for the pooled empagliflozin group and placebo. In each dataset, changes in ALT were analysed in all participants and in tertiles by ALT at baseline, and changes in AST were analysed in all participants and in tertiles by AST at baseline. Data are expressed as adjusted means (95% CI) or adjusted means ± SE.

In the EMPA-REG OUTCOME® trial, the contribution of changes in weight or HbA1c (individual and combined effects) to changes in ALT at weeks 28, 52 and 164 (median observation time) were assessed using MMRM analyses as described above, with additional factors for change in HbA1c, weight and, for weight analyses only, baseline weight by visit interaction. These contribution analyses were performed for all participants.

Results

Participants A total of 7020 participants with type 2 diabetes and established cardiovascular disease were treated in the EMPA-REG OUTCOME® trial (2333 in the placebo group and 4687 in the pooled empagliflozin group). Baseline
Participant characteristics have been previously described [15]. In brief, 71% of participants were male, 72% were white and 22% were of Asian race, mean ± SD BMI was 30.6 ± 5.3 kg/m², weight was 86.3 ± 18.9 kg and HbA₁c was 65 ±

**Fig. 1** Changes in ALT in the EMPA-REG OUTCOME® trial. (a) All patients. Adjusted mean ± SE change from baseline: −0.73 ± 0.25 with placebo and −2.96 ± 0.18 with empagliflozin at week 28; −1.80 ± 0.36 with placebo and −3.06 ± 0.25 with empagliflozin at week 164. (b) Patients in tertiles by baseline ALT. Adjusted mean ± SE change from baseline at week 28: 1.57 ± 0.51 with placebo and 1.51 ± 0.36 with empagliflozin in tertile 1; 0.29 ± 0.51 with placebo and −1.15 ± 0.35 with empagliflozin in tertile 2; −3.96 ± 0.48 with placebo and −8.33 ± 0.35 with empagliflozin in tertile 3. Adjusted mean ± SE change from baseline at week 164: 2.46 ± 0.72 with placebo and 2.32 ± 0.49 with empagliflozin in tertile 1; 0.04 ± 0.71 with placebo and −0.86 ± 0.48 with empagliflozin in tertile 2; −7.33 ± 0.65 with placebo and −9.54 ± 0.46 with empagliflozin in tertile 3. MMRM analysis in patients treated with at least one dose of study drug based on observed cases, including values after initiation of rescue medication. Baseline values are mean ± SE. Grey triangles and dashed lines, placebo; black squares and solid lines, empagliflozin. 

---

2158 Diabetologia (2018) 61:2155–2163

© Springer
29.0 ± 5.5 kg/m², weight was 78.6 ± 18.8 kg and HbA1c was 6.6 ± 0.8%. Mean ± SD BMI was 30.1 ± 5.3 kg/m², weight was 82.8 ± 19.2 kg and HbA1c was 7.92 ± 0.84%. Mean ± SD ALT was 26.2 ± 5.5 U/l and AST was 24.7 ± 11.6 U/l, respectively.

Data pooled from the 24-week trials included data from 2477 participants (825 in the placebo group and 1652 in the pooled empagliflozin group). Baseline participant characteristics in the individual trials have been previously described [16–19]. In the pooled dataset, 62% were male, 56% were of Asian race and 41% were white, baseline mean ± SD BMI was 29.0 ± 5.5 kg/m², weight was 78.6 ± 18.8 kg and HbA1c was 64 ± 9.3 mmol/mol (7.99 ± 0.85%). Mean ± SD ALT was 28.4 ± 17.2 U/l in the placebo group and 28.2 ± 15.7 U/l in the empagliflozin group, and AST was 23.1 ± 10.4 and 23.0 ± 15.3 U/l in the placebo group and 25.5 ± 13.8 U/l in the empagliflozin group, and AST was 63.0 ± 9.2 mmol/mol (7.92 ± 0.84%). Mean ± SD ALT was 31.2 ± 22.6 U/l in the glimepiride group and 31.9 ± 19.6 U/l in the empagliflozin group, and AST was 25.0 ± 12.8 and 24.7 ± 11.6 U/l, respectively.

**Changes in ALT** In the EMPA-REG OUTCOME® trial, ALT decreased from baseline to week 28 and thereafter remained stable in the empagliflozin group, and declined steadily and to a lesser extent in the placebo group (Fig. 1a). Mean ± SE changes from baseline were -2.96 ± 0.18 U/l in the empagliflozin group and -0.73 ± 0.25 in the placebo group at week 28 (adjusted mean difference: -2.22 [95% CI -2.83, -1.62]; p < 0.0001) and -3.06 ± 0.25 U/l and -1.80 ± 0.36 U/l, respectively, at week 164 (adjusted mean difference: -1.26 [95% CI -2.12, -0.40]; p = 0.0040) (Table 1).

Reductions in ALT were greatest in participants in the highest tertile of ALT at baseline (Fig. 1b), in whom the adjusted mean difference with empagliflozin vs placebo was -4.36 U/l (95% CI -6.11, -2.62; p < 0.0001) at week 28 and -2.22 U/l (95% CI -3.78, -0.66; p = 0.0053) at week 164 (adjusted mean difference: -3.06 U/l [95% CI -4.59, -1.54]; p < 0.0001).

**Table 1** Differences in changes from baseline ALT and AST with empagliflozin relative to placebo or glimepiride

| Trial | ALT (U/l) | AST (U/l) |
|-------|-----------|-----------|
| EMPA-REG OUTCOME® | | |
| Adjusted mean (95% CI) difference vs placebo in change from baseline at week 28 | | |
| All participants | -2.22 (−2.83, −1.62) | -1.01 (−1.48, −0.54) |
| p < 0.0001 | p < 0.0001 |
| Tertile 3 (highest tertile) by ALT/AST at baseline | -4.36 (−5.51, −3.21) | -1.53 (−2.35, −0.72) |
| p < 0.0001 | p = 0.0002 |
| Adjusted mean (95% CI) difference vs placebo in change from baseline at week 164 | | |
| All participants | -1.26 (−2.12, −0.40) | -0.66 (−1.45, 0.13) |
| p = 0.0040 | p = 0.1007 |
| Tertile 3 (highest tertile) by ALT/AST at baseline | -2.22 (−3.78, −0.66) | -0.99 (−2.34, 0.36) |
| p = 0.0053 | p = 0.1504 |
| Pooled 24-week placebo-controlled trial data | | |
| Adjusted mean (95% CI) difference vs placebo in change from baseline at week 24 | | |
| All participants | -3.15 (−4.11, −2.18) | -1.45 (−2.12, −0.78) |
| p < 0.0001 | p < 0.0001 |
| Tertile 3 (highest tertile) by ALT/AST at baseline | -5.60 (−7.41, −3.79) | -2.84 (−4.14, −1.54) |
| p < 0.0001 | p < 0.0001 |
| EMPA-REG H2H-SU | | |
| Adjusted mean (95% CI) difference vs glimepiride in change from baseline at week 28 | | |
| All participants | -4.88 (−6.68, −3.09) | -2.78 (−3.92, −1.64) |
| p < 0.0001 | p < 0.0001 |
| Tertile 3 (highest tertile) by ALT/AST at baseline | -7.14 (−10.11, −4.18) | -3.92 (−5.79, −2.04) |
| p < 0.0001 | p < 0.0001 |
| Adjusted mean (95% CI) difference vs glimepiride in change from baseline at week 104 | | |
| All participants | -4.28 (−6.11, −2.45) | -3.00 (−4.33, −1.67) |
| p < 0.0001 | p < 0.0001 |
| Tertile 3 (highest tertile) by ALT/AST at baseline | -6.03 (−9.02, −3.04) | -5.25 (−7.47, −3.03) |
| p < 0.0001 | p < 0.0001 |

MMRM analysis in participants treated with at least one dose of study drug based on observed cases, including values after initiation of rescue medication.
164 (Table 1). In the second tertile, differences with empagliflozin vs placebo in changes from baseline in ALT were −1.45 (95% CI −2.65, −0.24; p = 0.0188) at week 28 and −0.91 (95% CI −2.59, 0.77; p = 0.2903) at week 164. In the lowest tertile, changes from baseline in ALT were similar between empagliflozin and placebo at weeks 28 and 164 (Fig. 1b). Similar patterns of changes in ALT were observed with empagliflozin vs placebo in the pooled 24-week trial data (Fig. 2a and electronic supplementary material [ESM] Fig. 1), and with empagliflozin vs glimepiride over 104 weeks in the EMPA-REG H2H-SU trial (Fig. 2b, ESM Fig. 2).

In the EMPA-REG OUTCOME® trial, treatment differences in ALT were largely independent of concomitant changes in HbA1c or weight in the overall trial population (Table 2).

**Changes in AST** In the EMPA-REG OUTCOME® trial, AST decreased from baseline to week 28 and thereafter remained stable in the empagliflozin group, while there were no relevant changes in the placebo group (ESM Fig. 3a). Mean ± SE changes from baseline were −1.32 ± 0.14 U/l in the empagliflozin group and −0.31 ± 0.20 in the placebo group at week 28 (adjusted mean difference: −1.01 U/l [95% CI −1.48, −0.54]; p < 0.0001), and −1.17 ± 0.23 U/l and −0.51 ± 0.33 U/l, respectively at week 164 (adjusted mean difference: −0.66 U/l [95% CI −1.45, 0.13]; p = 0.1007) (Table 1). Reductions from baseline in AST with empagliflozin were greatest in participants in the highest tertile of AST at baseline (ESM Fig. 3b), in whom the adjusted mean difference with empagliflozin vs placebo was −1.53 U/l (95% CI −2.35, −0.72; p = 0.0002) at week 28 and −0.99 U/l (95% CI −2.34, 0.36; p = 0.1504) at week 164 (Table 1). Changes from baseline AST were similar between empagliflozin and placebo at weeks 28 and 164 in the second and third tertiles (ESM Fig. 3b). Similar patterns of changes in AST were observed with empagliflozin vs placebo in the pooled 24-week trial data (ESM Fig. 4), and with empagliflozin vs glimepiride over 104 weeks in the EMPA-REG H2H-SU trial (ESM Fig. 5). In all studies examined, while not compared statistically, changes in AST were of a substantially lower magnitude than changes in ALT (Table 1).

**Discussion**

Type 2 diabetes is often associated with NAFLD, which is reflected by increased liver aminotransferase levels. ALT levels above the upper limit of normal and AST levels lower than those of ALT are typical findings supporting the presence of NAFLD in real-life clinical practice in primary care [4]. Our analyses from three large datasets from clinical trials of empagliflozin in individuals with type 2 diabetes have shown that treatment with empagliflozin consistently lowered ALT and AST levels. The reductions in ALT observed with empagliflozin were consistently greater than the reductions in AST, more prominent in participants with the highest ALT levels at baseline and largely independent of changes in HbA1c and weight. Changes in ALT and AST were minimal in participants with the lowest levels at baseline, who would be predicted to have the lowest liver fat levels.

Transaminases, in particular ALT, are useful correlates of liver fat. The overall patterns of change in ALT observed with empagliflozin are broadly consistent with a reduction in liver fat [4]. The twin-cycle hypothesis of diabetes postulates that excess liver and pancreatic fat are major components of the pathogenesis of type 2 diabetes [25]. Furthermore, it has recently been shown that, among individuals with type 2 diabetes, those with a hospital record of NAFLD have an
increased risk of all-cause mortality, death from cardiovascular disease and incident/recurrent cardiovascular events than those without a record of liver disease [26]. Hence, any treatment that lowers liver fat and the risk of progression to more advanced liver disease could have important benefits for individuals with type 2 diabetes.

The mechanisms by which empagliflozin might reduce aminotransferases or liver fat are unclear. Data from animal models support a direct effect of empagliflozin on reducing liver fat and improving hepatic glucose handling. In db/db mice, glucose uptake in the liver and kidneys has been reported to be higher in mice treated with empagliflozin than in controls [27], and in a NASH model generated by administration of streptozotocin to C57BL/6J mice, empagliflozin attenuated the development of NASH via anti-steatotic and anti-inflammatory effects [28]. The SGLT2 inhibitor dapagliflozin has also been shown to improve markers of liver fat in individuals with type 2 diabetes and NASH [29]. Further emerging evidence, albeit from a much smaller trial, has linked treatment with other SGLT2 inhibitors to reductions in liver fat (and ALT) equivalent to those seen with pioglitazone in individuals with type 2 diabetes [30].

Liver fat was not measured directly in any of the studies used in our analyses. However, in a study using magnetic resonance spectroscopy, ALT levels were found to correlate reasonably well with the extent of liver fat in individuals with type 2 diabetes ($r = 0.66$), even though liver fat levels were disproportionately (200%) higher in those with type 2 diabetes than in control participants without diabetes at given ALT levels in the range of 50–200 U/l [9]. This suggests that in individuals with type 2 diabetes, reductions in ALT from higher baseline levels (equivalent to the top ALT tertile in our analyses) are more likely to be associated with meaningful reductions in liver fat. In the current analysis, the patterns of reduction, the greater effects observed when baseline ALT was higher and the consistent observations across three large datasets lend confidence that our findings reflect a real clinical action of empagliflozin. However, we accept that further trials are needed, including those that take histological measures of NASH in individuals with type 2 diabetes before and after treatment. Ongoing trials, including long-term trials of empagliflozin in individuals with heart failure (NCT03057977, NCT03057951) and chronic kidney disease [31], will provide additional data.

We also accept that ALT levels at baseline were measured at only a single point in time and that a sustained elevation in ALT is potentially a better marker of a higher level of liver fat. While overall reductions in ALT were modest, reductions with empagliflozin relative to placebo or sulfonylurea were in the order of 4–7 U/l in those with higher ALT levels at baseline, which appears meaningful. Finally, of course, we accept that other conditions that influence the liver, such as hepatitis or excess alcohol intake, can influence ALT and AST levels, although alcohol does so in a different pattern [4]. Furthermore, it is unlikely that the greater changes in ALT that we observed with empagliflozin vs placebo could occur via effects on subclinical hepatitis, which would be present in only a minority of individuals.

In conclusion, our results suggest that in individuals with type 2 diabetes, treatment with empagliflozin reduces liver aminotransferases, largely independent of changes in weight

### Table 2

| Week | Proportion of ALT-lowering effect of empagliflozin vs placebo that was independent of/associated with concomitant changes from baseline in HbA1c or weight | Independent (%) | Associated (%) |
|------|-------------------------------------------------------------------------------------------------|----------------|---------------|
| Week 28 | Change from baseline in HbA1c | 88.0 | 12.0 |
|       | Change from baseline in weight | 86.8 | 13.2 |
|       | Change from baseline in HbA1c and weight | 76.7 | 23.3 |
| Week 52 | Change from baseline in HbA1c | 82.6 | 17.4 |
|       | Change from baseline in weight | 79.0 | 21.0 |
|       | Change from baseline in HbA1c and weight | 66.2 | 33.8 |
| Week 164 | Change from baseline in HbA1c | 85.0 | 15.0 |
|        | Change from baseline in weight | 90.6 | 9.4 |
|        | Change from baseline in HbA1c and weight | 76.7 | 23.3 |

MMRM analysis in participants treated with at least one dose of study drug based on observed cases, including values after initiation of rescue medication.

HbA1c: $n$ analysed in placebo and empagliflozin groups, respectively = 2128 and 4308, at week 28; 2025 and 4123 at week 52; and 874 and 1904 at week 164.

Weight: $n$ analysed in placebo and empagliflozin groups, respectively = 2140 and 4336 at week 28; 2037 and 4146 at week 52; and 876 and 1907 at week 164.
and glycaemic control, and does so in a pattern that is potentially consistent with reductions in liver fat. These highly consistent trial findings add meaningfully to the emerging evidence from smaller trials on the effects of SGLT2 inhibitors on direct measures of liver fat, and collectively suggest a potential role for this class of drugs in managing NAFLD in type 2 diabetes. Further trials should now be promoted to enable an indication to be developed.

Acknowledgements Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by E. Ng and W. Morris (Fleishman Hillard Fishburn, London, UK), during the preparation of this article. Thanks also to L. Coyle (University of Glasgow) for additional support in the preparation of this article.

Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding The trials reported in this paper were funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance. Boehringer Ingelheim had a role in study design, data collection, data analysis, data interpretation and writing of the report. Eli Lilly and Company had no role in study design, data collection, data analysis, data interpretation or writing of the report.

Duality of interest NS has consulted for Boehringer Ingelheim, Eli Lilly, Janssen and Novo Nordisk, and received grants support from Boehringer Ingelheim. DF has received honoraria from Sanofi, Merck & Co., AstraZeneca, Eli Lilly and Boehringer Ingelheim. BZ has received research grants from Boehringer Ingelheim, AstraZeneca and Novo Nordisk, and honoraria from Janssen, Sanofi, Eli Lilly, Boehringer Ingelheim, Novo Nordisk and Merck. JTG and SH are employees of Boehringer Ingelheim.

Contribution statement NS, DF, JTG, and BZ contributed to the interpretation of data and writing of the manuscript. SH contributed to the analysis and interpretation of data and writing of the manuscript. All authors are fully responsible for all content and editorial decisions and were involved at all stages of manuscript development, and have approved the final version. SH is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29:113–119
2. Williamson RM, Price JF, Glancy S et al (2011) Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34:1139–1144
3. Dai W, Ye L, Liu A et al (2017) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 96:e1179
4. Sattar N, Forrest E, Preisser D (2014) Non-alcoholic fatty liver disease. BMJ 349:g4596
5. Perry RJ, Samuel VT, Petersen KF, Shulman GI (2014) The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510:84–91
6. Forlani G, Di BP, Mannucci E et al (2008) Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 31:146–152
7. Hanley AJ, Williams K, Festa A et al (2004) Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53:2623–2632
8. West J, Broussil G, Gazis A et al (2006) Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM 99:871–876
9. Kotronen A, Juviriens L, Hakkarainen A et al (2008) Liver fat is increased in type 2 diabetic patients and underestimared by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165–169
10. American Diabetes Association (2017) Comprehensive medical evaluation and assessment of comorbidities. Diabetes Care 40(Suppl 1):S25–S32
11. Bril F, Cusi K (2017) Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care 40:419–430
12. Belfort R, Harrision SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307
13. Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled Phase 2 study. Lancet 387:679–690
14. Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78–89
15. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
16. Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet Diabetes Endocrinol 1:208–219
17. Häring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:1650–1659
18. Häring HU, Merker L, Seewaldt-Becker E et al (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 36:3396–3404
19. Kovacs CS, Seshiah V, Swallow R et al (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 16:147–158
20. Rosenstock J, Jelaska A, Frappin G et al (2014) Improved glucose control with weight loss, lower insulin doses and reduced hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes. Diabetes Care 37:1815–1823
21. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ (2015) Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week
randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 17:936–948
22. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woeke HJ, Broedl UC (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, Phase 3 trial. Lancet Diabetes Endocrinol 2:691–700
23. Heise T, Jordan J, Wanner C et al (2016) Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther 38:2265–2276
24. Neeland IJ, McGuire DK, Chilton R et al (2016) Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 13:119–126
25. Taylor R (2008) Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 51:1781–1789
26. Wild SH, Walker JJ, Morling JR et al (2018) Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission. Diabetes Care 41:341–347
27. Kern M, Kloeting N, Mark M, Mayoux E, Klein T, Bluher M (2016) The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 65:114–123
28. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8:45
29. Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y (2017) Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 87:13–19
30. Ito D, Shimizu S, Inoue K et al (2017) Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 40:1364–1372
31. Boehringer Ingelheim (2017) Empagliflozin (Jardiance®) to be studied in chronic kidney disease. Available from www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 10 Jan 2018